New pill shows promise for Tough-to-Treat lymphoma
NCT ID NCT03593018
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tested an oral chemotherapy drug, azacitidine, against standard treatments in 86 patients with a rare type of T-cell lymphoma that had returned or not responded to prior therapy. The main goal was to see if the oral drug could delay cancer progression. The study is completed, and results will help determine if this pill offers a better option for these patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
oral azacitidine (a chemotherapy drug taken as a tablet)
What this could lead to
If successful, this could offer a new, more convenient treatment option for patients with this rare blood cancer that has stopped responding to prior therapy.
What could go wrong
This is a completed Phase 3 trial, but results are not yet widely reported. The drug may not improve survival compared to existing options, and side effects like nausea or low blood counts are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A. Z. Sint-Jan Brugge-Oostende AV
Bruges, Belgium
-
Aarhus University Hospital
Aarhus, Denmark
-
CH Annecy Genevois
Pringy, France
-
CHRU de Lille
Lille, France
-
CHRU de Nancy - Hôpital de Brabois
Vandœuvre-lès-Nancy, France
-
CHU Haut-Lévèque - Centre François Magendie
Pessac, France
-
CHU Henri Mondor
Créteil, France
-
CHU Lyon-Sud
Pierre-Bénite, France
-
CHU Pontchaillou
Rennes, France
-
CHU UCL Namur - Site Godinne
Yvoir, Belgium
-
CHU de Clermont-Ferrand - Hôpital Estaing
Clermont-Ferrand, France
-
CHU de Dijon
Dijon, France
-
CHU de Grenoble
Grenoble, France
-
CHU de Montpellier - Hôpital Saint-Eloi
Montpellier, France
-
CHU de Nantes - Hôtel Dieu
Nantes, France
-
Centre Henri Becquerel
Rouen, France
-
Churchill Hospital
Oxford, United Kingdom
-
Cliniques Universitaires de Bruxelles - Hôpital Erasme
Brussels, Belgium
-
Hôpital Necker
Paris, France
-
Hôpital Saint-Louis
Paris, France
-
IUCT - Oncopole
Toulouse, France
-
Institut d'Hématologie de Basse Normandie
Caen, France
-
Medical University of Vienna
Vienna, Austria
-
Nottingham City Hospital
Nottingham, United Kingdom
-
The Christie
Manchester, United Kingdom
-
University College London Hospital
London, United Kingdom
-
University Hospital for Internal Medicine - University Hospital Graz
Graz, Austria